FNP-223, previously known as ASN90, is a reversible and substrate-competitive O-GlcNAcase enzyme inhibitor. The oral investigational drug is expected to rapidly increase O-GlcNAcylated tau proteins, ...

When progressive supranuclear palsy (PSP), a rare neurodegenerative disorder, started affecting his movement, his wife and ...

Progressive supranuclear palsy (PSP) affects persons in their late 60s to 70s, because of the shrinkage of the upper ...